Jounce Therapeutics (JNCE) rapidly rising while having undervalued market cap

Most biotechs stocks are still in cash burning stage unlike some of them are earning and expanding by billions in actual value. Very interesting Jounce Therapeutics’ stock (NASDAQ: JNCE) is cheap and represents an undervalued company but has positive EPS and growing revenue. Both short and long-termed investors are obsessed with JNCE for a long time.

Partnering with Gilead actually pushes JNCE shares to soar at least 47% on over 30 million units. Until 22 June the stock has enjoyed reading higher but dark days have come after that day to pressure the price to $4.58.

Hopefully, September’s trading period may increase the stock more than $10 if further successful work gets done by both Gilead and JNCE.

Michael Rowels

Weekend Contributor. Writing for business and finance publishers has become his passion over the last decades after he completed a master's degree in Financial Management. Sharing some opinions and forecasts to thousands of readers is a routine job for him but he never promises to invest in one stock.